Neuroendocrine Tumor Treatment Is Estimated To Witness High Growth Owing To Opportunity In Novel Therapeutic Drugs
Neuroendocrine tumors (NETs) are a group of rare cancers that originate from neuroendocrine cells found throughout the body. Common symptoms of NETs include flushing, diarrhea, wheezing, and abdominal pain. Treatment options for NETs include somatostatin analogs, targeted therapy, chemotherapy, and surgery. Somatostatin analogs help control the symptoms caused by hormones released by NETs. Targeted therapy drugs work by blocking specific molecules involved in tumor growth and spread.
The global Neuroendocrine Tumor Treatment Market is estimated to be valued at Us$ 3 Bn In 2023 and is expected to exhibit a CAGR Of 8.4% over the forecast period 2023 To 2030, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
The rise in incidence rates and mortality caused by NETs indicates a high unmet need that can be addressed through continuous research and development of novel therapeutic drugs. The opportunity for novel targeted drugs and combination therapies holds significant potential for enhancing therapeutic outcomes in NETs management. Drugs targeting various pathways involved in tumor growth, angiogenesis and metastasis can provide more effective treatment options. Furthermore, immunotherapy drugs that help activate the body's natural defenses against cancer also represent a promising opportunity area. Overall, the development of next-generation treatment modalities offers high growth prospects for the neuroendocrine tumor treatment market over the forecast period.
Porter's Analysis
Threat of new entrants: The neuroendocrine tumor treatment market offers high entry barriers due to the high capital requirements and stringent regulatory procedures. Bargaining power of buyers: Individual buyers have low bargaining power due to lack of substitute treatment options and life-saving nature of treatment. Bargaining power of suppliers: Suppliers have moderate bargaining power due to availability of generic formulations and existence of alternative supply sources. Threat of new substitutes: Limited threat due to lack of new treatment alternatives for neuroendocrine tumors. Competitive rivalry: High due to ongoing clinical trials for new and efficacious drugs.
SWOT Analysis
Strengths: Rising incidence of neuroendocrine tumors, new drug approvals and pipeline drugs. Weaknesses: High costs of treatment, limited awareness. Opportunities: Emerging Asian markets, scope for combination therapies. Threats: Patent expirations, stringent regulations.
Key Takeaways
The Global Neuroendocrine Tumor Treatment Market Demand is expected to witness high growth driven by increasing incidence of NETs and improved treatment options. North America currently dominates the market due to developed healthcare infrastructure and high treatment adoption. The Asia Pacific region is expected to grow at a high rate driven by growing economies, rising healthcare spending and increasing patient population.
Key players operating in the neuroendocrine tumor treatment market are Svenska Cellulosa AB, DSG International Ltd., First Quality Enterprises, Inc., Kimberly-Clark Corporation, Abena A/S, Attends Healthcare Products, Inc., Unicharm Corporation, Kao Corporation, Ontex Group, Chiaus (Fujian) Industrial Development Co Ltd and others. Regional players are focusing on partnerships while global players are involved in new product development through mergers & acquisitions and clinical trials.
Get more insights on this topic :